Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes

Clinica Chimica Acta

Volumn 346, Issue 2, 2004, Pages 119-128

  Wiviott, Stephen D ^a   De Lemos, James A ^b   Morrow, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; ANP; BNP; Myocardial infarction; Natriuretic peptides; NT pro BNP; Review; Unstable angina

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; CREATINE KINASE MB; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; TROPONIN;

AMINO TERMINAL SEQUENCE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HEMODYNAMICS; HUMAN; LABORATORY DIAGNOSIS; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NECROSIS; PROGNOSIS; RISK ASSESSMENT;

ANGINA;

EID: 3142530269     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.04.004     Document Type: Review

References (48)

1. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 350(7):2004 (Feb. 12);655-663
2. Kangawa K., Fukuda A., Kubota I., et al. Human atrial natriuretic polypeptides (hANP): purification, structure synthesis and biological activity. J. Hypertens Suppl. 2(3):1984 (Dec.);S321-S323
3. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90(1):1994;195-203
4. Hosoda K., Nakao K., Mukoyama M., et al. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension. 17(6 Pt 2):1991 (Jun.);1152-1155
5. Qi W., Mathisen P., Kjekshus J., et al. Natriuretic peptides in patients with aortic stenosis. Am. Heart J. 142(4):2001 (Oct.);725-732
6. Edwards B.S., Zimmerman R.S., Schwab T.R., et al. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ. Res. 62(2):1988 (Feb.);191-195
7. de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet. 362(9380):2003 (Jul. 26);316-322
8. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J. Card. Fail. 7(1):2001;21-29
9. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347(3):2002;161-167
10. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J. Am. Coll. Cardiol. 36(5):2000 (Nov. 1);1587-1593
11. Morita E., Yasue H., Yoshimura M., et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 88(1):1993 (Jul.);82-91
12. Arakawa N., Nakamura M., Aoki H., et al. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J. Am. Coll. Cardiol. 27(7):1996;1656-1661
13. Omland T., Aakvaag A., Bonarjee V.V., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 93(11):1996;1963-1969
14. Talwar S., Squire I.B., Downie P.F., et al. Profile of plasma N-terminal proBNP following acute myocardial infarction: correlation with left ventricular systolic dysfunction. Eur. Heart J. 21(18):2000;1514-1521
15. Richards A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 97(19):1998;1921-1929
16. Kikuta K., Yasue H., Yoshimura M., et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am. Heart J. 132(1 Pt 1):1996 (Jul.);101-107
17. Talwar S., Squire I.B., Downie P.F., et al. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart. 84(4):2000;421-424
18. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J. Am. Coll. Cardiol. 41(8):2003 (Apr. 16);1264-1272
19. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345(14):2001;1014-1021
20. Cannon C.P., McCabe C.H., Wilcox R.G., et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 102(2):2000 (Jul. 11);149-156
21. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. 344(25):2001;1879-1887
22. Omland T., de Lemos J.A., Morrow D.A., et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am. J. Cardiol. 89(4):2002;463-465
23. James S.K., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. A global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation. 108(3):2003 (Jul. 22);275-281
24. Omland T., Persson A., Ng L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 106(23):2002 (Dec. 3);2913-2918
25. Jernberg T., Stridsberg M., Venge P., et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J. Am. Coll. Cardiol. 40(3):2002;437-445
26. Morrow D.A., Antman E.M., Snapinn S.M., et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur. Heart J. 23(3):2002;223-229
27. Morrow D.A., Antman E.M., Tanasijevic M., et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI 11B substudy. J. Am. Coll. Cardiol. 36(6):2000;1812-1817
28. Hamm C.W., Heeschen C., Goldmann B., et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 fab antiplatelet therapy in unstable refractory angina (CAPTURE) study investigators. N. Engl. J. Med. 340(21):1999;1623-1629
29. Hamm C.W., Ravkilde J., Gerhardt W., et al. The prognostic value of serum troponin T in unstable angina. N. Engl. J. Med. 327(3):1992;146-150
30. Morrow D.A., Cannon C.P., Rifai N., et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 286(19):2001;2405-2412
31. Jernberg T., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J. Am. Coll. Cardiol. 42(11):2003 (Dec. 3);1909-1916
32. Hama N., Itoh H., Shirakami G., et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 92(6):1995 (Sep. 15);1558-1564
33. Toth M., Vuorinen K.H., Vuolteenaho O., et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am. J. Physiol. 266(4 Pt 2):1994 (Apr.);H1572-H1580
34. D'Souza S.P., Yellon D.M., Martin C., et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am. J. Physiol. Heart Circ. Physiol. 284(5):2003 (May);H1592-H1600
35. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Elevation of B-type natriuretic peptide in the setting of myocardial ischemia. Circulation. 104:2001;II-485
36. Marumoto K., Hamada M., Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin. Sci. (Lond). 88(5):1995;551-556
37. Kyriakides Z.S., Markianos M., Michalis L., et al. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin. Cardiol. 23(4):2000;285-288
38. Wong G.C., Morrow D.A., Murphy S., et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy - thrombolysis in myocardial infarction. Circulation. 106(2):2002 (Jul. 9);202-207
39. Morrow D.A. Troponins in patients with acute coronary syndromes: biologic, diagnostic, and therapeutic implications. Cardiovasc. Toxicol. 1:2001;105-110
40. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336(14):1997;973-979
41. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342(12):2000;836-843
42. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med. 331(7):1994;417-424
43. Lindahl B., Toss H., Siegbahn A., et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease. N. Engl. J. Med. 343(16):2000;1139-1147
44. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction. J. Am. Coll. Cardiol. 31(7):1998;1460-1465
45. Morrow D.A., Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation. 108(3):2003 (Jul. 22);250-252
46. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 105(15):2002;1760-1763
47. de Lemos J.A., Morrow D.A. B-type natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation. 106(23):2002;2868-2870
48. Clerico A., Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin. Chem. 50(1):2004 (Jan.);33-50